Grant of Options

RNS Number : 8456K

Immupharma PLC

12 July 2017

 

                                                                                                                                                                           12 July 2017

Grant of Options

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over 1,400,000 ordinary shares of 10p each ("Ordinary Shares") to certain of its non-executive Directors representing 1.06% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The exercise price for these options is 56.75p pence being the closing middle market share price on 11 July 2017. The options will vest after three years and are exercisable between three and ten years from the date of grant.   

The amount of options granted to non-executive Directors are summarised in the following table:

Director	Ordinary Shares under Option
Tim McCarthy	1,000,000
Franco di Muzio	200,000
Stephane Mery	200,000

Following this grant of all options on the above date, the total number of share options outstanding will be 8,233,850 representing 6.2% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

Messrs McCarthy, di Muzio and Mery currently have the following interests in issued Ordinary Shares:

Director	Number of Ordinary Shares	% of issued share capital at 11 July 2017
Tim McCarthy	38,462	0.03%
Franco di Muzio	99,412	0.08%
Stephane Mery	21,490	0.02%

Following the grant of the options referred to above, Messrs McCarthy, di Muzio and Mery will have the following interests in options over the Company's Ordinary Shares:

Director	Number of Ordinary Shares under option	Exercise Price	Expiry Date
Tim McCarthy	500,000 1,000,000	43.88p 56.75p	02.06.2026 12.07.2027
Franco di Muzio	100,000 100,000 100,000 200,000	76.80p 86.50p 43.88p 56.75p	31.07.2017 04.02.2019 02.06.2026 12.07.2027
Stephane Mery	100,000 200,000	43.88p 56.75p	02.06.2026 12.07.2027

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Ends

For further information please contact: ImmuPharma plc (www.immupharma.org) + 44 (0) 20 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma + 44 (0) 7721 413496 Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking [phone]

 

END

 

 

DSHRTMLTMBABMMR